Welcome to our dedicated page for Intellia Therapeutics SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Intellia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Intellia Therapeutics's regulatory disclosures and financial reporting.
Intellia Therapeutics, Inc. director Jesse Goodman reported equity awards consisting of common stock and stock options as part of compensation. He received 9,200 shares of Common Stock$0.00 per share33,559 shares
Goodman also received a stock option for 13,300 shares of Common Stock$12.89 per share13,300 shares
Intellia Therapeutics director Brian Goff received new equity compensation awards. He was granted 9,200 restricted stock units, each representing one share of common stock, and stock options covering 13,300 shares at an exercise price of $12.89. Following the grant, he directly holds 32,609 common shares, and the options vest in full on the earlier of one year from grant or the next annual stockholder meeting.
Intellia Therapeutics, Inc. director Fred E. Cohen received new equity-based compensation. He was granted 9,200 restricted stock units, each representing a contingent right to one share of Intellia common stock, increasing his direct common stock holdings to 216,653 shares.
He was also granted a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Intellia Therapeutics director William J. Chase received new equity awards. On June 9, he was granted 9,200 restricted stock units, each representing the right to receive one share of Intellia common stock upon vesting.
He also received a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting. After the RSU grant, Chase directly holds 143,893 common shares.
Intellia Therapeutics director Muna Bhanji received new equity awards. She was granted 9,200 shares of common stock based on restricted stock units, bringing her direct common stock holdings to 36,403 shares.
She was also granted stock options for 13,300 shares at an exercise price of $12.89 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expire on June 8, 2036.
Intellia Therapeutics, Inc. reported the results of its Annual Meeting of stockholders held on June 9, 2026. Stockholders voted on three proposals that had been described in the company’s Proxy Statement.
For the election of directors, Muna Bhanji received 57,065,465 votes for and 1,610,941 against, Brian Goff received 46,090,644 for and 12,582,130 against, and Jesse Goodman received 43,004,221 for and 15,686,289 against, each with additional abstentions and 30,124,178 broker non-votes. A separate proposal received 87,833,534 votes for, 779,540 against, and 249,592 abstentions, with no broker non-votes. Another proposal received 44,806,637 votes for, 13,821,404 against, 110,447 abstentions, and 30,124,178 broker non-votes. No other matters were submitted to stockholders.
Intellia Therapeutics reported first quarter 2026 results alongside major clinical milestones. In the Phase 3 HAELO trial, a one-time infusion of lonvo-z reduced hereditary angioedema attacks by 87% versus placebo over six months, with 62% of treated patients attack free and therapy free.
Intellia has begun a rolling BLA submission for lonvo-z and is targeting a potential U.S. launch in the first half of 2027. The FDA lifted clinical holds on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z in ATTR amyloidosis, and patient screening has resumed.
Financially, Q1 2026 collaboration revenue was $15.0 million and net loss was $96.2 million, or $0.81 per share. Cash, cash equivalents and marketable securities were $517.2 million as of March 31, 2026, and an April underwritten equity offering added approximately $207 million in gross proceeds, supporting operations at least into 2028.
Intellia Therapeutics entered an underwriting agreement for a public offering of 16,744,187 shares of common stock at $10.75 per share, with underwriters exercising a 30‑day option for an additional 2,511,628 shares. The company estimates net proceeds of about $194.6 million.
Intellia plans to use the funds to advance clinical development and prepare for commercial launch of its lead programs, support other pipeline research, pursue potential acquisitions, and for working capital and general corporate purposes. It expects these proceeds, together with existing cash and collaboration funding, to fund operations at least into 2028.
Intellia also reported preliminary unaudited cash, cash equivalents and marketable securities of about $517.2 million as of March 31, 2026, including roughly $33.6 million in net proceeds from at‑the‑market stock sales during the quarter.